The site of the Media Sphera Publishers contains materials intended solely for healthcare professionals.
By closing this message, you confirm that you are a certified medical professional or a student of a medical educational institution.

Login
EN
+7 (495) 482-4118
+7 (495) 482-0604
+8 800 101-59-87
  • (toll-free number for subscriptions)
    Mon-Fri from 10 a.m. to 6 p.m.

  • © 1998-2025
+7 (495) 482-43-29
EN
All journals
Journal
Year
Year
Search result: 0

Selivanova L.S.

Endocrinology Research Centre, Moscow, Russia

Volganova K.S.

Endocrinology Research Center, Ministry of Health of Russia, Moscow, Russia

Abrosimov A.Iu.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

Telomerase reverse transcriptase (TERT) promoter mutations in the tumors of human endocrine organs: Biological and prognostic value

Authors:

Selivanova L.S., Volganova K.S., Abrosimov A.Iu.

More about the authors

Journal: Russian Journal of Archive of Pathology. 2016;78(1): 62‑69

DOI: 10.17116/patol201678162-68

Views: 1075

Downloaded: 73

Download PDF (RU)
Contact the author
Table of contents

To cite this article:

Selivanova LS, Volganova KS, Abrosimov AIu. Telomerase reverse transcriptase (TERT) promoter mutations in the tumors of human endocrine organs: Biological and prognostic value. Russian Journal of Archive of Pathology. 2016;78(1):62‑69. (In Russ.)
https://doi.org/10.17116/patol201678162-68

Подписка 2025 (Russian Journal of Archive of Pathology)
МСФ на ЯМ
Close metadata

The analysis of the data available in the literature has shown that telomerase reverse transcriptase TERT promoter may serve as promising markers of malignancy, aggressive disease course, and poor prognosis for malignant tumors of endocrine organs. Considering the established association of mutations with tumors having a poor prognosis (high-grade and anaplastic carcinoma of the thyroid), it is reasonable to perform prognostic-value investigations in a group of low-grade thyroid carcinomas that may occasionally recur and may be resistant to radioactive iodine therapy, i.e. can demonstrate a poor course and prognosis. TERT promoter mutations may be a specific marker of the clinically aggressive forms of adrenocortical carcinoma, but the determination of its diagnostic value calls for additional investigations that will have the larger number cases and establish the association with clinical features and survival rates.

Keywords:

tumors of endocrine organs
TERT promoter mutations
biological value
prognosis

Authors:

Selivanova L.S.

Endocrinology Research Centre, Moscow, Russia

Volganova K.S.

Endocrinology Research Center, Ministry of Health of Russia, Moscow, Russia

Abrosimov A.Iu.

FGU Éndokrinologicheskiĭ nauchnyĭ tsentr, Moskva

List of references:

  1. Hayflick L. The limited in vitro lifetime of human diploid cell strains. Experimental Cell Research. 1965;37(3):614-636. doi:10.1016/0014-4827(65)90211-9.
  2. Hayflick L, Moorhead P. The serial cultivation of human diploid cell strains. Experimental Cell Research. 1961;25(3):585-621.  doi:10.1016/0014-4827(61)90192-6.
  3. Blackburn E. Structure and function of telomeres. Nature. 1991;350(6319):569-573.  doi:10.1038/350569a0.
  4. Greider C. Telomerase is processive. Molecular and Cellular Biology. 1991;11(9):4572-4580.
  5. Szostak J, Blackburn E. Cloning yeast telomeres on linear plasmid vectors. Cell. 1982;29(1):245-255. doi:10.1016/0092-8674(82)90109-x.
  6. Xie Z, Jay K, Smith D et al. Early telomerase inactivation accelerates aging independently of telomere length. Cell. 2015;160(5):928-939. doi:10.1016/j.cell.2015.02.002.
  7. Konishi A, de Lange T. Cell cycle control of telomere protection and NHEJ revealed by a ts mutation in the DNA-binding domain of TRF2. Genes & Development. 2008;22(9):1221-1230. doi:10.1101/gad.1634008.
  8. de Lange T. How shelterin solves the telomere end-protection problem. Cold Spring Harbor Symposia on Quantitative Biology. 2010;75(0):167-177. doi:10.1101/sqb.2010.75.017.
  9. Pfeiffer V, Lingner J. Replication of telomeres and the regulation of telomerase. Cold Spring Harbor Perspectives in Biology. 2013;5(5):a010405-a010405. doi:10.1101/cshperspect.a010405.
  10. Armanios M, Blackburn E. The telomere syndromes. Nat Rev Genet. 2012;13(10):693-704. doi:10.1038/nrg3246.
  11. Kyo S, Takakura M, Fujiwara T, Inoue M. Understanding and exploiting hTERT promoter regulation for diagnosis and treatment of human cancers. Cancer Science. 2008;99(8):1528-1538. doi:10.1111/j.1349-7006.2008.00878.x.
  12. Heidenreich B, Rachakonda P, Hemminki K, Kumar R. TERT promoter mutations in cancer development. Current Opinion in Genetics & Development. 2014;24:30-37. doi:10.1016/j.gde.2013.11.005.
  13. Killela P, Reitman Z, Jiao Y et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proceedings of the National Academy of Sciences USA. 2013;110(15):6021-6026. doi:10.1073/pnas.1303607110.
  14. Lee K, Higgins H, Qureshi A. Familial risk of melanoma and links with other cancers. Melanoma Management. 2015;2(1):83-89. doi:10.2217/mmt.14.34.
  15. Huang F, Hodis E, Xu M, Kryukov G, Chin L, Garraway L. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013;339(6122):957-959.  doi:10.1126/science.1229259.
  16. Berger M, Hodis E, Heffernan T et al. Melanoma genome sequencing reveals frequent PREX2 mutations. Nature. 2012;485(7399):502-506. doi:10.1038/nature11071.
  17. Horn S, Figl A, Rachakonda P et al. TERT promoter mutations in familial and sporadic melanoma. Science. 2013;339(6122):959-961. doi:10.1126/science.1230062.
  18. Griewank K, Murali R, Puig-Butille J et al. TERT promoter mutation status as an Independent prognostic factor in cutaneous melanoma. Journal of the National Cancer Institute. 2014;106(9).pii:dju246-dju246. doi:10.1093/jnci/dju246.
  19. Borah S, Xi L, Zaug A et al. TERT promoter mutations and telomerase reactivation in urothelial cancer. Science. 2015;347(6225): 1006-1010. doi:10.1126/science.1260200.
  20. Allory Y, Beukers W, Sagrera A et al. Telomerase reverse transcriptase promoter mutations in bladder cancer: high frequency across stages, detection in urine, and lack of association with outcome. European Urology. 2014;65(2):360-366. doi:10.1016/j.eururo.2013.08.052.
  21. Hurst C, Platt F, Knowles M. Comprehensive mutation analysis of the TERT promoter in bladder cancer and detection of mutations in voided urine. European Urology. 2014;65(2):367-369. doi:10.1016/j.eururo.2013.08.057.
  22. Gandolfi G, Ragazzi M, Frasoldati A, Piana S, Ciarrocchi A, Sancisi V. TERT promoter mutations are associated with distant metastases in papillary thyroid carcinoma. European Journal of Endocrinology. 2015;172(4):403-413. doi:10.1530/eje-14-0837.
  23. Landa I, Ganly I, Chan T et al. Frequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the disease. The Journal of Clinical Endocrinology & Metabolism. 2013;98(9):E1562-E1566. doi:10.1210/jc.2013-2383.
  24. Liu T, Wang N, Cao J et al. The age- and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2013;33(42):4978-4984. doi:10.1038/onc.2013.446.
  25. Liu X, Bishop J, Shan Y et al. Highly prevalent TERT promoter mutations in aggressive thyroid cancers. Endocrine Related Cancer. 2013;20(4):603-610. doi:10.1530/erc-13-0210.
  26. Haglund F, Juhlin C, Brown T et al. TERT promoter mutations are rare in parathyroid tumors. Endocrine Related Cancer. 2015;22(3):L9-L11. doi:10.1530/erc-15-0121.
  27. Shi X, Liu R, Qu S et al. Association of TERT Promoter mutation 1,295,228 C>T with BRAF V600E mutation, older patient age, and distant metastasis in anaplastic thyroid cancer. The Journal of Clinical Endocrinology & Metabolism. 2015;100(4):E632-E637. doi:10.1210/jc.2014-3606.
  28. Liu X, Qu S, Liu R et al. TERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancer. The Journal of Clinical Endocrinology & Metabolism. 2014;99(6):E1130-E1136. doi:10.1210/jc.2013-4048.
  29. Vinagre J, Almeida A, Pópulo H et al. Frequency of TERT promoter mutations in human cancers. Nat Comms. 2013;4. doi:10.1038/ncomms3185.
  30. Melo M, da Rocha A, Vinagre J et al. TERT promoter mutations are a major Indicator of poor outcome in differentiated thyroid carcinomas. The Journal of Clinical Endocrinology & Metabolism. 2014;99(5):E754-E765. doi:10.1210/jc.2013-3734.
  31. Liu T, Brown T, Juhlin C et al. The activating TERT promoter mutation C228T is recurrent in subsets of adrenal tumors. Endocrine Related Cancer. 2014;21(3):427-434. doi:10.1530/erc-14-0016.
  32. Elder E, Elder G, Larsson C. Pheochromocytoma and functional paraganglioma syndrome: No longer the 10% tumor. Journal of Surgical Oncology. 2005;89(3):193-201. doi:10.1002/jso.20177.
  33. Else T, Giordano T, Hammer G. Evaluation of telomere length maintenance mechanisms in adrenocortical carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2008;93(4):1442-1449. doi:10.1210/jc.2007-1840.
  34. Pereira S, Maximo V, Coelho R, Soares P, Sobrinho-Simoes M, Monteiro MP. TERT promoter mutations and TERT expression in normal and tumoral adrenocortical tissues. Available at: https://endo.confex.com/endo/2014endo/webprogram/paper16770.html
  35. Papathomas T, Oudijk L, Zwarthoff E et al. Telomerase reverse transcriptase promoter mutations in tumors originating from the adrenal gland and extra-adrenal paraganglia. Endocrine Related Cancer. 2014;21(4):653-661. doi:10.1530/erc-13-0429.
  36. Juhlin C, Goh G, Healy J et al. Whole-exome sequencing characterizes the landscape of somatic mutations and copy number alterations in adrenocortical carcinoma. The Journal of Clinical Endocrinology & Metabolism. 2015;100(3):E493-E502. doi:10.1210/jc.2014-3282.
  37. Muller H. The remarking of chromosomes. Collect Net. 1938;13(8):181-198.
  38. McClintock B. The stability of broken ends of chromosomes in Zea Mays. Genetics. 1941;26(2):234-282.
  39. Blackburn E, Gall J. A tandemly repeated sequence at the termini of the extrachromosomal ribosomal RNA genes in Tetrahymena. Journal of Molecular Biology. 1978;120(1):33-53. doi:10.1016/0022-2836(78)90294-2.
  40. Olovnikov A.M. Printsip marginotomii v matrichnom sinteze polinukleotidov. Doklad Akademii Nauk SSSR. 1971;201(6):1496-1499.
  41. Watson J. Origin of concatemeric T7 DNA. Nat New Biol. 1972;239(94):197-201.
  42. Harley C. Telomere loss: mitotic clock or genetic time bomb? Mutation Research/DNAging. 1991;256(2-6):271-282. doi:10.1016/0921-8734(91)90018-7.
  43. Harley C, Sherwood S. Telomerase, checkpoints and cancer. Cancer Surv. 1997;29:263-284.
  44. Freund A, Zhong F, Venteicher A et al. Proteostatic control of telomerase function through TRiC-mediated folding of TCAB1. Cell. 2014;159(6):1389-1403. doi:10.1016/j.cell.2014.10.059.
  45. Cukusic A, Skrobot Vidacek N, Sopta M, Rubelj I. Telomerase regulation at the crossroads of cell fate. Cytogenet Genome Res. 2009;122(3-4):263-272.
  46. Cong Y, Wright W, Shay J. Human telomerase and its regulation. Microbiology and Molecular Biology Reviews. 2002;66(3):407-425. doi:10.1128/mmbr.66.3.407-425.2002.
  47. Wong M, Wright W, Shay J. Alternative splicing regulation of telomerase: a new paradigm? Trends in Genetics. 2014;30(10):430-438. doi:10.1016/j.tig.2014.07.006.
  48. Daniel M, Peek G, Tollefsbol T. Regulation of the human catalytic subunit of telomerase (hTERT). Gene. 2012;498(2):135-146. doi:10.1016/j.gene.2012.01.095.
  49. Davy P, Allsopp R. Stem cell maintenance and the imperative to understand telomerase regulation. Austin J Anat. 2014;1(5):2.
  50. Xing M, Liu R, Liu X et al. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. Journal of Clinical Oncology. 2014;32(25):2718-2726. doi:10.1200/jco.2014.55.5094.
  51. Labussiere M, Boisselier B, Mokhtari K et al. Abstract 2234: Combined analysis of TERT, EGFR and IDH status define distinct prognostic classes of GBM. Cancer Res. 2014;74(19, Suppl.):2234-2234. doi:10.1158/1538-7445.am2014-2234.
  52. Wang N, Liu T, Sofiadis A et al. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer. 2014;120(19):2965-2979. doi:10.1002/cncr.28800.
  53. Liu R, Xing M. Diagnostic and prognostic TERT promoter mutations in thyroid fine-needle aspiration biopsy. Endocrine Related Cancer. 2014;21(5):825-830. doi:10.1530/erc-14-0359.

Close metadata

Contact the author
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.

Email Confirmation

An email was sent to test@gmail.com with a confirmation link. Follow the link from the letter to complete the registration on the site.

Email Confirmation

Contact us
If you have any questions, complaints or suggestions, please use this feedback form.
Email
Message
The publishing house "Media Sphere" does not provide treatment services, does not give recommendations on contacting medical institutions and specific specialists, on the prescription of medicines and dietary supplements.
Submit Application

You can become an author of one of our magazines, send a request and we will consider it in during the day.

Name
Phone
E-mail
Message
Login
Registration
E-mail
Password
Forgot Password?

Log in to the site using your account in one of the services

Password recovery
E-mail
Login
Register


We use cооkies to improve the performance of the site. By staying on our site, you agree to the terms of use of cооkies. To view our Privacy and Cookie Policy, please. click here.